District and county (autonomous counties) Development and Reform Commission, municipal medical institutions, affiliated hospital of the Third Military Medical University, troops stationed in the garrison, hospitals for employees of large-scale enterprises and public institutions, and production and business units of pharmaceuticals:
According to the "Notice of the National Development and Reform Commission on Adjusting the Listed Drugs Listed by the National Development and Reform Commission," and other related issues (Development and Reform Prices [2010] No. 429), "Notice of the National Development and Reform Commission General Office on Further Strengthening Drug Price Management" (Shangfa Electric Power [2010] No. 195) and the “Supplementary Notice of the National Development and Reform Commission General Office on Strengthening the Management of Drug Prices and Other Issues†(Shangfa Electric Power (2010) No. 214) and other series of documents to further strengthen me The city’s drug price management and standardization of drug price behaviors are hereby notified as follows:
1. Further improve the government's pricing drug price management system 1. For drugs that are included in the government's management and sold in the administrative area of ​​the city, the drug production company (or the entrusted drug business unit) must report prices to the Bureau (required for drug prices) For related materials, please refer to appendix. Our Bureau will release the retail price information of drugs to the public through Chongqing Price Information Network. Our Bureau will timely formulate and publish the price of drugs according to relevant policy regulations.
2. For the medicines included in the pricing scope of our city and authorized by the National Development and Reform Commission for pricing in our city, the bureau will adjust the price once every 2-3 years in principle. During the period of centralized adjustment of prices, the production and operation costs and market supply and demand will be significant. As a result of the changes, the Bureau adjusted the prices in due course. Pharmaceutical production and operation companies must submit copies of tax-included factory price invoices stamped with official seals, and prices and related price/cost data set by the provincial-level price authorities in their places of origin to our bureau for adjustment of prices. The Bureau will strictly review the pricing of medicines according to the relevant pricing procedures of the country.
3. According to the relevant drug price management policy, the relevant enterprises shall report to the SIPO for the record after establishing the trial sales price for drugs that have been incorporated into the government's management and meet the production (import agency) companies' own test sales prices.
2. The management of medical institutions that further strengthen drug sales and price increase behaviors (excluding basic medical and health institutions implementing the basic drug system) and pharmaceutical retail units must strictly comply with the "Chongqing Price Bureau's Notice on Further Improving Drug Price Management Standards "(Zhai Price [2006] No. 490) stipulates that the maximum retail price and the rate of sale of drugs for sale (amount) shall be subject to double control, that is, neither the prescribed maximum retail price nor the prescribed rate of increase (amount) shall be exceeded. When implementing basic drug prices, the government-run medical and health institutions must strictly follow the specific retail prices of the essential drugs for bid-winning drugs. The basic medical and health institutions that implement the basic drug system must strictly follow the bid price of the essential drugs for winning bids.
III. Market adjustment price Drugs no longer issue price information In accordance with relevant requirements, the SIPO has stopped the price information of market-regulated drugs, which has previously been issued according to the price of the market-regulated drug price specified in the document [2007] No. 89. Abolished. Each drug production and sales entity shall follow the principle of fairness, legality, honesty and credit in the sale of market-adjusted price drugs, establish its own prices, and strictly implement the national drug price-related policies; sales of drugs must be clearly marked.
Fourth, to strengthen the dynamic monitoring of drug market prices The competent pricing departments of all districts and counties should strengthen the dynamic monitoring of the market price of pharmaceuticals. If it is found that the actual purchase and sale prices of drugs differ greatly from the prices announced and announced by the government, they must be promptly reflected to the Bureau. Take timely measures to reduce the retail price of related drugs.
V. Strengthening supervision and inspection of drug prices The competent price departments of all districts and counties shall perform drug price supervision duties according to law, further intensify supervision and inspection, and supervise the medical institutions and drug production and operation entities to strictly implement the relevant drug price regulations. Those who violate relevant regulations must be promptly investigated and dealt with in accordance with law, and the legitimate rights and interests of the people must be protected. Typical cases must be publicly disclosed.
The above provisions shall be implemented as of the date of issuance of this Notice. If any of the previous provisions contravenes this Notice, this notice shall prevail.
According to the "Notice of the National Development and Reform Commission on Adjusting the Listed Drugs Listed by the National Development and Reform Commission," and other related issues (Development and Reform Prices [2010] No. 429), "Notice of the National Development and Reform Commission General Office on Further Strengthening Drug Price Management" (Shangfa Electric Power [2010] No. 195) and the “Supplementary Notice of the National Development and Reform Commission General Office on Strengthening the Management of Drug Prices and Other Issues†(Shangfa Electric Power (2010) No. 214) and other series of documents to further strengthen me The city’s drug price management and standardization of drug price behaviors are hereby notified as follows:
1. Further improve the government's pricing drug price management system 1. For drugs that are included in the government's management and sold in the administrative area of ​​the city, the drug production company (or the entrusted drug business unit) must report prices to the Bureau (required for drug prices) For related materials, please refer to appendix. Our Bureau will release the retail price information of drugs to the public through Chongqing Price Information Network. Our Bureau will timely formulate and publish the price of drugs according to relevant policy regulations.
2. For the medicines included in the pricing scope of our city and authorized by the National Development and Reform Commission for pricing in our city, the bureau will adjust the price once every 2-3 years in principle. During the period of centralized adjustment of prices, the production and operation costs and market supply and demand will be significant. As a result of the changes, the Bureau adjusted the prices in due course. Pharmaceutical production and operation companies must submit copies of tax-included factory price invoices stamped with official seals, and prices and related price/cost data set by the provincial-level price authorities in their places of origin to our bureau for adjustment of prices. The Bureau will strictly review the pricing of medicines according to the relevant pricing procedures of the country.
3. According to the relevant drug price management policy, the relevant enterprises shall report to the SIPO for the record after establishing the trial sales price for drugs that have been incorporated into the government's management and meet the production (import agency) companies' own test sales prices.
2. The management of medical institutions that further strengthen drug sales and price increase behaviors (excluding basic medical and health institutions implementing the basic drug system) and pharmaceutical retail units must strictly comply with the "Chongqing Price Bureau's Notice on Further Improving Drug Price Management Standards "(Zhai Price [2006] No. 490) stipulates that the maximum retail price and the rate of sale of drugs for sale (amount) shall be subject to double control, that is, neither the prescribed maximum retail price nor the prescribed rate of increase (amount) shall be exceeded. When implementing basic drug prices, the government-run medical and health institutions must strictly follow the specific retail prices of the essential drugs for bid-winning drugs. The basic medical and health institutions that implement the basic drug system must strictly follow the bid price of the essential drugs for winning bids.
III. Market adjustment price Drugs no longer issue price information In accordance with relevant requirements, the SIPO has stopped the price information of market-regulated drugs, which has previously been issued according to the price of the market-regulated drug price specified in the document [2007] No. 89. Abolished. Each drug production and sales entity shall follow the principle of fairness, legality, honesty and credit in the sale of market-adjusted price drugs, establish its own prices, and strictly implement the national drug price-related policies; sales of drugs must be clearly marked.
Fourth, to strengthen the dynamic monitoring of drug market prices The competent pricing departments of all districts and counties should strengthen the dynamic monitoring of the market price of pharmaceuticals. If it is found that the actual purchase and sale prices of drugs differ greatly from the prices announced and announced by the government, they must be promptly reflected to the Bureau. Take timely measures to reduce the retail price of related drugs.
V. Strengthening supervision and inspection of drug prices The competent price departments of all districts and counties shall perform drug price supervision duties according to law, further intensify supervision and inspection, and supervise the medical institutions and drug production and operation entities to strictly implement the relevant drug price regulations. Those who violate relevant regulations must be promptly investigated and dealt with in accordance with law, and the legitimate rights and interests of the people must be protected. Typical cases must be publicly disclosed.
The above provisions shall be implemented as of the date of issuance of this Notice. If any of the previous provisions contravenes this Notice, this notice shall prevail.
The Urine Drainage Bag set consists of a drainage bag and a suction device. Qhy-a is the single drainage bag, and qhy-b is the drainage bag + suction device. The drainage bag consists of the bag body, Catheter , lifting lug, joint, guard cap, drainage port, drainage bottom plug, anti-reflux device, and current limiting clip.The suction device is composed of negative pressure bottle, drainage tube joint, suction tube joint, suction connection pipe, automatic drainage device, drainage port and bag body.Should be sterile.
It is used for the collection of body fluids ( blood , gastric juice, etc.), secretions (sputum, flushing fluid, etc.) and human excreta (urine, etc.) in hospital, clinical departments and during surgery or after surgery.
Urine drainage bag, Urinary Drainage Bags,Urine Collection Bags, dialysis drainage bag, drainage bag
Urine Drainage Bag
Catheter Bag,Bard Urinary Drainage Bag,Catheter Urine Bag,Disposable Catheter Bag,Urine collection bag with T cross valve, urine collection bag
Huali Technology Co., Ltd , https://www.jlhualitech.com